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Introduction: Multiple vaccination visits and administrations can be stressful for infants, parents and
healthcare providers. Multivalent combination vaccines can deliver the required number of antigens in
fewer injections and clinic visits, while vaccine co-administration can also reduce the number of visits.
This non-inferiority study was undertaken to evaluate the feasibility of co-administering a combined
measles-mumps-rubella-varicella (MMRV) vaccine with conjugated meningococcal C (MenC) vaccine
in a large cohort of healthy Italian toddlers.
Methods: Healthy subjects aged 13–15 months were randomized (2:1:1) to receive single doses of either:
co-administered MMRV + MenC at the same visit (MMRV + MenC group); or MMRV followed 42 days
later by MenC (MMRV group); or MenC followed 42 days later by MMRV (MenC group). Blood samples
were collected before and 43 days after vaccination. Antibody titers against MMRV were measured using
ELISA. Functional-anti-meningococcal-serogroup activity (rSBAMenC) was assessed using a serum bacte-
ricidal test. Solicited local and general reactions were recorded for up to 4 and 42 days post-vaccination,
respectively. Non-inferiority of MMRV + MenC to MMRV (post-dose-1 seroconversion rates) and MMRV
+ MenC to MenC (post-dose-1 seroprotection rates) was achieved if the lower limit (LL) of the 95% con-
fidence interval (CI) for the group difference was P10% for each antigen.
Results: 716 subjects were enrolled in the study. At 42 days post-vaccination, the MMRV seroconversion
rates were 99.3% (measles), 94.5% (mumps), 100% (rubella) and 99.7% (varicella) in the MMRV + MenC
group, and 99.4%, 93.2%, 100% and 100%, respectively, in the MMRV group. The seroprotection rates
against rSBA-MenC were 98.3% in the MMRV + MenC group and 99.3% in the MenC group. Non-
inferiority was reached for all the vaccine antigens. The safety profiles were as expected for these vac-
cines.AIDID);
ct.it (M.
llegrino),
rchetti).
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those elicited by MMRV or MenC alone and support vaccination of children with both vaccines at a single
visit.
Clinical Trials registration: NCT01506193.
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(http://creativecommons.org/licenses/by/4.0/).1. Introduction
In Italy, from 2011 to 2015, the annual number of reported
measles cases fell from 5181 (8.5/100,000 population) [1] to 247
(0.4/100,000) [2], but notification rates are still higher than in
many other European countries [2]. Data from 2010 to 2011
showed that, in Italy, the vast majority (96%) of measles cases were
in people who were either unvaccinated or incompletely vacci-
nated; and that adolescents and young adults were most affected
(i.e. those that did not receive childhood measles-mumps-rubella
(MMR) vaccination as part of the national immunization program,
as it was only included in 1999) [3]. The uptake for MMR is
particularly concerning, as P95% uptake is necessary to interrupt
endemic transmission of measles [2]. However, Italian data from
2014 show MMR vaccine uptake levels of approximately 87% (first
dose) [4] and 83% (second dose) [5].
A two-dose varicella (V) universal vaccination program has
been implemented in selected Italian regions. First-dose vaccina-
tion uptake is around 51–84% by age 2 years [4]. However, uptake
was lower in regions where MMR + V was used rather than
measles-mumps-rubella-varicella (MMRV) [6]. Conjugated
meningitis C (MenC) vaccine uptake in the second year of life is
also suboptimal in Italy, at approximately 75% [4].
As a maximum of two vaccine injections per visit is considered
ideal in Italy [7], a potential tool to increase vaccine uptake is to
use combination vaccines alongwith co-administration. The current
Italian vaccination recommendations for children aged 13 months
include: (1) MMRV or MMR + V; (2) MenC or conjugated meningo-
coccal ACWY (MenACWY) vaccine; and (3) meningococcal B (MenB)
vaccine [8]. Thus, co-administration of MMRV plus a meningococcal
conjugate vaccine at one visit might be beneficial. However,
information on the co-administration of MMRV and conjugate
meningococcal vaccines is sparse. To date, only two studies have
examined the co-administration of MMRV with vaccines against
MenC: either meningococcal ACWY-tetanus toxoid conjugate vac-
cine (MenACWY-TT) [9] orMenACWY-CRM [10]. Both studies found
that the vaccines could be co-administered without affecting the
immunogenicity or safety profiles of either vaccine [9,10].
The aim of the study reported here was to provide data on the
co-administration of MMRV and MenC in Italy. This non-
inferiority study was therefore undertaken to compare the
immunogenicity and safety of co- and separate administration of
MMRV and MenC vaccines in healthy Italian toddlers.2. Materials and methods
2.1. Study design and subjects
Open phase IIIb, randomized, study conducted at 13 centers in
Italy between February 2012 and March 2014. Healthy male or
female subjects, aged 13–15 months, were randomized (2:1:1)
to receive either single doses of MMRV and MenC vaccines
administered concomitantly as separate injections on the same
day (MMRV + MenC Group); a single dose of MMRV at one visit
followed 42 days later by a single dose of MenC vaccine (MMRV
Group); or a single dose of MenC at one visit followed 42 days later
by a single dose of MMRV vaccine (MenC Group).Subjects were excluded if they had: received any investigational
drug/vaccine 30 days before the study vaccine or immunosuppres-
sive medication/immunoglobulins/blood products for P14 days
within 6 months; major congenital defects; chronic illness or a
family history of immunodeficiency; human immunodeficiency
virus; symptoms of acute illness or fever; previous vaccination/
history/known exposure to MMRV and/or Neisseria meningitidis
serogroup C diseases.
The study adhered to Good Clinical Practice, the Declaration of
Helsinki, and local Italian rules and regulations. Independent ethics
committees and/or institutional review boards at each participat-
ing center reviewed and approved all study-related documents.
Parents/guardians of subjects provided written informed consent
before any study-related procedures were performed.
2.2. Study objectives
The co-primary objectives of the study were to show the
non-inferiority of: co-administering MMRV vaccine with MenC
conjugate vaccine compared to MMRV vaccine alone; and
co-administering MenC vaccine with MMRV compared to MenC
conjugate vaccine alone. Secondary objectives included the
42-day post-vaccination immunogenicity and tolerability of each
study vaccine.
2.3. Study vaccines
A single 0.5 mL dose of MMRV vaccine (Priorix-TetraTM, GSK, Bel-
gium; batch numbers: AD01B698A, AD01C132D, AD01B538B,
A71CA677A, AMRVA138A, AMRVA200B, and AMRVA162B; com-
prising a lyophilized cake which was reconstituted with the dilu-
ent from a pre-filled syringe before administration) was
administered subcutaneously in the deltoid region of the upper
arm. A single 0.5 mL dose of MenC CRM-197 conjugated vaccine
(Meningitec, Nuron Biotech; batch numbers: F32046, F15126 and
G26516) was administered intramuscularly into the upper thigh.
The needle sets provided for MMRV and MenC vaccines were
8 mm 25G5 and 1.25 mm 25G, respectively.
2.4. Immunogenicity assessment
Blood samples were collected before and 43 days after vaccina-
tion. Antibody titers against MMRV were measured using commer-
cial enzyme-linked immunosorbent assays (ELISA) – (Enzygnos
Dade Behring, Marburg, Germany) with cut-off values of
150 mIU/mL (measles), 231 U/mL (mumps), 4 IU/mL (rubella) and
25 mIU/mL (varicella). Anti-meningococcal serogroup activity
(rSBA-MenC) was measured using an in-house serum bactericidal
test (cut-off: P1:8). For measles, mumps, rubella and varicella,
subjects who were seropositive for each assay prior to vaccination
did not contribute to the seroconversion rate or geometric mean
concentration (GMC) calculations.
2.5. Safety/reactogenicity assessment
Parents/guardians used diary cards to record solicited injection
site symptoms for 4 days after each vaccine and solicited general
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thema, parotid/salivary gland swelling, signs of meningism, febrile
convulsions) and for 15 days post-MenC vaccination (drowsiness,
irritability/fussiness, loss of appetite).
Unsolicited symptoms were recorded for 43 days after each
dose and serious adverse events (SAEs) were recorded throughout
the study.
The intensity of all symptoms was graded on a scale of 0–3;
where ‘‘Grade 0” was none/as usual, ‘‘Grade 1” was mild, ‘‘Grade
2” was moderate and ‘‘Grade 3” was severe. Grade 3 solicited
symptoms were defined as: pain: cried when limb was moved or
a spontaneously painful limb; redness and swelling: injection site
surface diameter >20 mm; fever: rectal temperature >39.5 C;
rash: >150 lesions; irritability/fussiness: crying that cannot be
comforted/prevented normal activity; drowsiness: which prevents
normal activity; loss of appetite: not eating at all. Unsolicited
symptoms (including SAEs) were defined as grade 3 if they pre-
vented normal daily activity.
2.6. Statistical analysis
All statistical analyses were performed using Statistical Analysis
Software (SAS) version 9.2.
A sample size of 720 subjects was planned (MMRV + MenC:
360; MMRV: 180; MenC: 180), considering an approximately 10%
non-inferiority margin for all antigens. The 2:1:1 blocking random-
ization scheme ensured that the balance between treatments was
maintained.
The non-inferiority of MMRV + MenC versus MMRV vaccine
alone was met if the lower limit (LL) of the standardized asymp-
totic 95% confidence intervals (CIs) for the post-vaccination differ-
ence in percentage of seroconverted subjects between the two
groups (MMRV + MenC minus MMRV) was P10% for each vac-
cine antigen. Similarly, for MMRV + MenC versus MenC vaccine,
the post-vaccination difference in the percentages of seroprotected
subjects between the two groups (MMRV + MenC minus MenC)
was P10% for rSBA-MenC antibodies.
The immunogenicity analysis was performed on the according-
to-protocol (ATP) cohort, which included all subjects with available
pre- and post-vaccination serology results, who were seronegative
for at least one vaccine antigen and complied with study proce-
dures. Seroconversion rates (antibody concentration/titer Pcut-
off value in initially seronegative subjects), seroprotection rates
(rSBA-MenC antibody titerP1:8), GMCs and geometric mean titers
(GMTs) against each vaccine antigen were calculated with 95% CIs
(cut-offs given above).
The safety analysis was performed on the total vaccinated
cohort (TVC) which included all vaccinated subjects.3. Results
3.1. Demographics
Of 716 enrolled subjects (MMRV + MenC: 351; MMRV: 183;
MenC: 182), 626 were included in the ATP cohort for immuno-
genicity (MMRV + MenC: 315; MMRV: 168; MenC: 143; Fig. 1).
The baseline demography did not differ by study group. The
overall mean age was 13.4 ± 0.6 months and 53.7% were male.
The study population was predominantly Caucasian (81.3%).
3.2. Immunogenicity
At 42 days post-vaccination, the seroconversion rates for the
MMRV antigens in the MMRV + MenC group were 99.3%, 94.5%,
100% and 99.7%, respectively. In the group which received MMRValone, the MMRV seroconversion rates were 99.4%, 93.2%, 100%
and 100%, respectively (Table 1). As the LL of the 95% CI for the
MMRV + MenC minus MMRV group difference was above 10%;
non-inferiority was demonstrated (Table 1).
At 42 days post-vaccination, the seroprotection rate for rSBA-
MenC in the MMRV + MenC group was 98.3% compared with
99.3% in the subjects who received MenC alone (Table 1). As the
LL of the 95% CI for the MMRV + MenC minus MenC group differ-
ence was above 10%; non-inferiority was demonstrated (Table 1).
GMCs and GMT in the MMRV + MenC group were generally
similar to those in the MMRV group (Table 1). However, it should
be noted that no statistical analysis of these comparisons was
planned in the study protocol, and no predefined non-inferiority
criteria were set, so eventual comparison of these groups should
be interpreted with caution.3.3. Reactogenicity and safety
Within 4 days of vaccination, injection site redness was the
most commonly reported solicited local symptom, with 29.8% sub-
jects (MenC site) and 27.3% subjects (MMRV site) in the MMRV
+ MenC group, and with 23.2% subjects for the MMRV group
(Fig. 2).
Irritability/fussiness was the most frequently reported solicited
general symptom during the 15-day post-vaccination period and
was experienced by 55.7%, 58.8% and 49.1% of subjects in the
MMRV + MenC, MMRV and MenC groups, respectively (Fig. 3).
Grade 3 irritability/fussiness (crying that could not be comforted/
prevented) was recorded in 8.9%, 7.3% and 4.1% of subjects,
respectively.
MMRV-specific solicited general symptoms reported during the
43-day post-vaccination period included parotid gland swelling in
0.9% (MMRV + MenC group), 2.3% (MMRV group); and meningism/
febrile convulsion in 0.3% (MMRV + MenC group) and 0.6% (MenC
group) of subjects. The percentages of subjects who developed
fever during the 43-day post-vaccination period were: 64.9%
(MMRV + MenC), 64.4% (MMRV) and 37.4% (MenC). The character-
istic peak in fever at 5–12 days post MMRV vaccination was
observed in the MMRV + MenC and MMRV groups (Fig. 4). Very
few subjects received prophylactic antipyretic medication:
MMRV + MenC: 0.6%; MMRV: 0.5%; none for MenC.
Only two subjects in the MMRV + MenC group reported febrile
convulsions. The first occurred 8 days after vaccination, was con-
sidered related to vaccination, but was of mild intensity. The sec-
ond occurred 28 days after vaccination, was a grade 3 SAE, but
was considered not related to vaccination. Rather, the investigator
thought that it was caused by a viral infection, as blood analyses
showed leukocytosis.
Rash was observed in 27.0% of MMRV + MenC subjects, 23.2% in
the MMRV group and 8.8% in the MenC group. Varicella-like rash
was observed in 1.8%, 0.6% and 0.6% subjects, respectively and
measles/rubella-like rash was seen in 11.9%, 9.0% and 1.2%, respec-
tively. Grade 3 rash (>150 lesions) was reported in 60.6% subjects.
At least one unsolicited symptom was reported for 27.6%
(MMRV + MenC), 33.3% (MMRV) and 22.5% (MenC) of subjects.
The most common symptoms were: pharyngitis in the MMRV
+ MenC and MenC subjects (n = 16 [4.6%] and n = 9 [4.9%], respec-
tively) and cough, pharyngitis and diarrhea (n = 10; 5.5% for each
symptom) in the MMRV group.
SAEs were reported in 12 subjects (MMRV + MenC: 6; MMRV:
4; MenC: 2). None were causally related to vaccination and no sub-
ject withdrew due to SAE. There were no deaths during the study.
Fig. 1. Subject disposition. ATP, according to protocol; MenC, conjugated meningitis C vaccine; MMRV, measles, mumps, rubella, and varicella vaccine; TVC, total vaccinated
cohort.
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Several trials have already shown the feasibility of co-
administering MMRV with other vaccines: MenACWY-TT [9],
MenACWY-CRM [10], reduced-antigen content diphtheria-
tetanus-acellular pertussis-inactivated poliovirus vaccine (dTpa-
IPV) or full-strength DTPa-IPV [11], 10-valent pneumococcal non-
typeable Haemophilus influenzae protein D conjugate vaccine
(PHiD-CV) [12], 4CMenB [13], or H. influenzae type b conjugate-
hepatitis B vaccine (Hib/HepB) and diphtheria-tetanus-acellular
pertussis vaccines (DTaP) [14]. However, this is the first study com-
paring the immunogenicity and safety of co-administered MMRV
+ MenC vaccines in healthy Italian children. The results show that
the immune responses to MMRV and rSBA antibodies were non-Table 1
Immunological responses after MMRV + Men C, MMRV or MenC, at 42 days post-vaccinati
Antibody Group N SC (%) (95% CI) GMC (95
Measles (P150 mIU/mL) MMRV + MenC 307 99.3 (99.7; 99.9) 2943.6 (2
MMRV 163 99.4 (96.6; 100) 3158.5 (2
Mumps (P231 U/mL) MMRV + MenC 309 94.5 (91.3; 96.8) 1530.7 (1
MMRV 162 93.2 (88.2; 96.6) 1591.3 (1
Rubella (P4 IU/mL) MMRV + MenC 309 100 (98.8; 100) 40.2 (37.
MMRV 164 100 (97.8; 100) 44.9 (40.
Varicella (P25 mIU/mL) MMRV + MenC 300 99.7 (98.2; 100) 156.3 (14
MMRV 159 100 (97.7; 100) 145.2 (12
Antibody Group N SP (%) (95% CI) GMT (95
rSBA-MenC (P8 1/DIL) MMRV + MenC 291 98.3 (96.0; 99.4) 491.7 (41
MenC 143 99.3 (96.2; 100) 586.4 (47
N: number of subjects in each group.
SC (%): seroconversion (percentage of subjects with titerP specified value).
SP (%): seroprotection (percentage of subjects with titerP specified value).
95% CI: 95% confidence interval.
GMC: geometric mean antibody concentration.
GMT: geometric mean antibody titer.inferior after the combined administration compared with those
elicited by either MMRV or MenC vaccines alone.
The immune responses to all vaccine antigens were high in all
groups and were comparable to those observed by Vesikari et al.
when combined MMRV + MenACWY was studied [9]. Similar
results were seen in a study conducted in healthy children in the
US where the MMRV vaccine was administered at the same time
as other vaccines [15].
The study vaccines were generally well tolerated and clinically
acceptable safety profiles were observed. The expected peak in
fever within 5–12 days after MMRV dosing in our study is compa-
rable with previous reports [16,17]. The pattern of fever was com-
parable between the MMRV + MenC and MMRV groups and higher
than the MenC group. Similar observations were reported by Vesi-on (ATP cohort for immunogenicity).
% CI) Difference in SC rate (95% CI) (MMRV + MenC minus MMRV)
691.5; 3219.2) 0.04 (1.82; 2.78)
749.7; 3628.0)
368.4; 1712.1) 1.29 (3.04; 6.67)
346.2; 1881.0)
3; 43.3) 0.00 (1.23; 2.29)
6; 49.6)
3.9; 169.8) 0.33 (1.87; 2.03)
9.5; 162.8)
% CI) Difference in SP rate (95% CI) (MMRV + MenC minus MenC)
6.5; 580.4) 1.02 (3.39; 2.24)
9.3; 717.6)
Fig. 2. Incidence of solicited local symptoms during four days after vaccination
with MMRV + MenC, MMRV or MenC (total vaccinated cohort).
Fig. 3. Incidence of solicited general symptoms reported during the 43-day post-
vaccination follow-up period (total vaccinated cohort).
Fig. 4. Prevalence of any fever by day (d
4282 P. Durando et al. / Vaccine 34 (2016) 4278–4284kari et al. when ACWY-TT + MMRV and MMRV alone vaccines were
given to children aged 12–23 months [9]. It is worth nothing that
the MMRV fever pattern was not modified by co-administration
of mono- or tetravalent-conjugated meningococcal vaccines.
Although Schink et al. [18] showed a relationship between
MMRV and febrile convulsion, and other studies have shown an
increased risk of febrile convulsions with combined MMRV vaccine
[19,20], two subjects in our MMRV + MenC group experienced a
febrile convulsion. One occurred on day 8, was mild in intensity,
and was considered related to vaccination; the other occurred on
day 28, was a grade 3 SAE, but was not considered to be related
to the vaccine. The rate of febrile convulsions observed in Germany
for Priorix-Tetra (2.18/10,000 vaccinees) [18] is consistent with the
range (0.87/10,000–3.37/10,000) recorded by the Veneto region
vaccine surveillance system (Canale Verde) from 2008 to 2014
[21]. Further, a recent observational study carried out in the
Veneto Region, in which over 10,000 forms were completed by
mothers, showed that the overall rate of SAEs, including febrile
convulsions, was no worse for MMRV as compared to MMR + V
[22]. Although not statistically powered, the rate of febrile convul-
sion was comparable for both strategies [risk ratio (95% CI) 0.80
(0.30–2.15)]. The Veneto study also showed that mothers of tod-
dlers who received MMR + V rather than MMRV had higher levels
of stress and risk perception [22].
Measles seroconversion was high in both MMRV and MMRV
+ MenC groups and GMCs were also unaffected. It has been
reported that GMC values for measles are higher following MMRV
vaccine administration as compared to MMR + V [23].
Rash is a common adverse event following the administration of
varicella vaccine, affecting between 3% and 17% of subjects [24–
26]. Unsurprisingly, rash (any) was higher in the subjects who
received MMRV vaccine as compared to MenC vaccine in our study.
Most other adverse events were generally mild-to-moderate; and
no vaccine-related SAEs were reported.
A potential limitation of this study is that it was conducted in a
single country; further studies might be needed to extrapolate
these results to other populations.
In conclusion, the co-administration of the MMRV vaccine with
MenC was immunogenic and well tolerated in Italian toddlers.
Such co-administration in routine clinical practice would reduceays 0–42) (total vaccinated cohort).
P. Durando et al. / Vaccine 34 (2016) 4278–4284 4283the number of required clinic visits and has the potential to
improve vaccine acceptance, compliance and uptake.
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